Corindus Vascular Robotics will present benefits of its CorPath System during May 29 symposium, “Robotic Precision: A Tool to Standardize Today’s Cath Lab,” at SCAI 2014, May 28 –31

Waltham, MA (PRWEB) May 28, 2014

Corindus Vascular Robotics, the leader in precision vascular robotics, will showcase its CorPath System at the upcoming Society for Cardiovascular Angiography and Interventions (SCAI) 2014 annual scientific session, May 28 –31 in Las Vegas, NV. CorPath is the first FDA-cleared medical device to bring robotic precision and accuracy to coronary angioplasty to help optimize clinical outcomes. Interventional cardiologists working at leading hospitals and healthcare organizations will share insight on the implementation of robotic technology in cath lab and discuss the benefits the CorPath System offers patients and physicians.

“Robotic Precision: A Tool to Standardize Today’s Cath Lab,” a breakfast symposium on Thursday, May 29, will highlight the physician presentations at 6:30 a.m. PDT at rooms I-II of the Pompeian Ballroom at Caesars Palace Hotel.

Ehtisham Mahmud, M.D., director, Sulpizio Cardiovascular Center-Medicine, UC San Diego, and Giora Weisz, M.D., Shaare Zedek Medical Center will moderate the symposium, titled “Robotic Precision: A Tool to Standardize Today’s Cath Lab.” The symposium will present clinical data and cases demonstrating robotic-assisted percutaneous coronary intervention (PCI) procedures. Attendees will develop an understanding of the benefits of robotic precision as well as the reduced radiation exposure for physicians enabled by the technology. The symposium will close with an audience Q&A and discussion on the ways robotics can enhance angioplasties.

“Tremendous advances have been made in the stent technologies and pharmacologic therapies for percutaneous coronary intervention. However, minimal changes in the procedural technique itself have occurred since the initial description of PCI. Robotic assisted-PCI opens a new frontier in the field enabling improved precision and new novel techniques for performing PCI. Additionally, there is a growing body of evidence that interventionalists face an elevated risk of brain tumors and other malignancies. Robotic-assisted PCI with CorPath is a unique tool that protects the interventionalists by reducing radiation exposure and simultaneously enhancing procedural efficiency.” said Ehtisham Mahmud, MD.

“Corindus is committed to improving clinical outcomes for patients by empowering physicians with the robotic precision and safety afforded by CorPath,” said David Handler, President and CEO of Corindus Vascular Robotics. “This symposium will showcase the critical benefits to both patients and physicians that are possible via robotic-assisted angioplasties.”

“Robotic Precision: A Tool to Standardize Today’s Cath Lab” will feature the following agenda and speakers:

For a hands-on demonstration of robotic angioplasty with the CorPath System, register here and visit SCAI booth #307.

For more information on the symposium, “Robotic Precision: A Tool to Standardize Today’s Cath Lab,” click here. To see the complete SCAI 2014 agenda, please visit http://www.scai.org/SCAI2014/default.aspx.

###

About Corindus Vascular Robotics
Corindus Vascular Robotics is the global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company’s FDA-cleared CorPath® 200 System is the first medical device that offers interventional cardiologists PCI procedure control from an interventional cockpit. With the CorPath System, Corindus brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through improper stent placement. Corindus stands behind its technology with a “One Stent Promise,” offering a $1,000 credit to hospitals that use two or more stents per lesion in PCI procedures performed with the CorPath System. For additional information, visit http://www.corindus.com